Related by context. All words. (Click for frequent words.) 71 bone metastases 70 micrometastases 69 basal cell carcinoma BCC 69 colorectal carcinoma 68 nonmelanoma skin cancers 67 HER2 overexpression 67 osteosarcomas 67 distant metastasis 67 endometrial hyperplasia 67 metastatic renal cell carcinoma 67 differentiated thyroid 66 androgen deprivation 66 mTOR inhibitors 66 prostate cancer CaP 66 endometrial carcinoma 66 breast carcinoma 66 metachronous 66 endometrial cancers 66 carcinoid 65 neoadjuvant therapy 65 epithelial tumors 65 metastatic malignant melanoma 65 xenograft models 65 pancreatic carcinoma 65 recurrent glioblastoma multiforme GBM 65 cisplatin resistant 65 HGPIN 65 relapsed ovarian cancer 65 GISTs 65 alkylating agent 65 ADPKD 65 HER2 positive breast cancer 65 cervical carcinoma 65 HER2 positive metastatic breast 65 Malignant Melanoma 65 malignant pleural mesothelioma 65 metastatic disease 65 metastatic RCC 65 pulmonary metastases 65 hepatocellular carcinoma 65 squamous cell carcinoma SCC 65 skeletal metastases 65 lobular carcinoma 65 metastatic prostate cancer 65 recurrent NSCLC 65 metastases 65 metastatic bladder 64 malignancy 64 Irinotecan 64 Metastatic 64 precursor lesions 64 recurrent glioblastoma multiforme 64 anti angiogenic therapy 64 Hodgkin lymphoma HL 64 brain metastases 64 acute leukemias 64 biochemical relapse 64 curative resection 64 colorectal adenoma 64 ovarian carcinoma 64 Acute myeloid leukemia 64 cilengitide 64 metastatic malignant 64 malignancies 64 VEGF receptor 64 hypercalcemia 64 premalignant lesions 64 HER2 positive cancers 64 liver metastases 64 nonmetastatic 64 node metastases 64 cisplatin chemotherapy 64 superficial bladder cancer 64 lung carcinomas 64 CYT# potent vascular disrupting 64 liver metastasis 64 squamous cell lung cancer 64 recurrent ovarian 63 hepatocellular carcinoma HCC 63 YONDELIS 63 pancreatic adenocarcinoma 63 metastatic colorectal 63 gastrointestinal stromal tumors GIST 63 LHRH agonists 63 leukemia AML 63 antiproliferative effects 63 pre malignant lesions 63 HRPC 63 tumor necrosis 63 receptor tyrosine kinase inhibitor 63 adenomatous 63 Trastuzumab 63 depsipeptide 63 EGFR inhibitors 63 PSMA ADC 63 pituitary adenomas 63 Bezielle 63 sarcomatoid 63 locoregional recurrence 63 chemoradiotherapy 63 metastatic neuroendocrine tumors 63 Hepatocellular Carcinoma HCC 63 breast cancer metastasis 63 serous ovarian cancer 63 neoplastic lesions 63 HuLuc# 63 angiogenesis inhibitor 63 EGFR TKI 63 Symadex 63 chemopreventive agent 63 biochemical recurrence 63 gemcitabine Gemzar 63 thymoma 63 gastric adenocarcinoma 63 pertuzumab 63 pheochromocytoma 63 Glioblastoma multiforme GBM 63 lupus nephritis 63 PCa 63 TNFα 63 metastasis 63 DFMO 63 Chronic lymphocytic leukemia 63 castrate resistant prostate cancer 63 mycophenolate mofetil 63 prostate cancer CRPC 63 premalignant 63 vidofludimus 63 castration resistant prostate cancer 63 dasatinib Sprycel 63 BRCA deficient 63 Enzastaurin 63 Tavocept 63 cyclin E 63 gastrointestinal stromal tumors 63 ductal carcinomas 63 Papillary 63 microtubule targeting 63 neoadjuvant chemotherapy 63 squamous cell cancers 63 renal cell carcinomas 63 urothelial cancer 63 chemoresistant 63 heavily pretreated 63 enzastaurin 63 GnRH agonists 63 preoperative chemotherapy 63 medullary thyroid cancer 63 androgen independent 63 metastatic lesions 63 cancer mCRC 63 trabectedin 63 antiangiogenic 63 neoplasm 63 tumor recurrence 63 PSADT 63 urothelial carcinoma 63 erlotinib Tarceva ® 63 recurrent glioblastoma 63 trans retinoic acid 62 epithelial ovarian 62 axitinib 62 antiangiogenic therapy 62 Sezary syndrome 62 adenocarcinomas 62 HER2 positive 62 multikinase inhibitor 62 prostate adenocarcinoma 62 estramustine 62 posaconazole 62 anti leukemic 62 lymphoid malignancies 62 dexrazoxane 62 anti fibrotic 62 Hydroxyurea 62 panobinostat 62 PAOD 62 hormone refractory 62 MAPK pathway 62 invasive carcinoma 62 GW# [003] 62 thalidomide Thalomid 62 VEGF inhibitors 62 carcinoid tumors 62 Natalizumab 62 SCCHN 62 metastatic castration resistant 62 colorectal tumors 62 oral FTY# 62 cabazitaxel 62 adenomatous polyps 62 intestinal metaplasia 62 acute GvHD 62 advanced adenoma 62 gastrointestinal stromal tumor 62 colorectal adenocarcinoma 62 carcinoids 62 operable breast cancer 62 LHRH receptor positive 62 mRCC 62 recurrent GBM 62 pCR 62 neoadjuvant 62 NMIBC 62 cytoprotective 62 MGd 62 peritoneal carcinomatosis 62 Squamous 62 arterial calcification 62 Epidermal Growth Factor Receptor 62 Brain metastases 62 Crizotinib 62 advanced adenomas 62 BRAF inhibitor 62 bladder cancers 62 Beta catenin pathway 62 hepatocellular carcinomas 62 pegylated liposomal doxorubicin 62 hepatocellular cancer 62 bladder carcinoma 62 AEG# 62 histologic subtype 62 paclitaxel Taxol 62 seminomas 62 goserelin 62 renal flares 62 AA Amyloidosis 62 lung metastasis 62 PXD# 62 thromboembolic disease 62 Cutaneous T 62 BZL# 62 Aplidin 62 tumor regressions 62 induces apoptosis 62 myeloproliferative diseases 62 breast carcinomas 62 Tarvacin 62 urothelial 62 CMV infection 62 advanced metastatic prostate 62 indolent NHL 62 nonmelanoma skin cancer 62 disease progression 62 antitumor efficacy 62 neovascularization 62 decitabine 62 biliary tract cancer 62 pediatric malignancies 62 ixabepilone 62 ErbB2 positive 62 leukemic cell 62 EGFr 62 carcinoma 62 micrometastasis 62 axillary lymph nodes 62 p# biomarker 62 Carcinoma 62 gastric carcinoma 62 B Raf 62 CD3 monoclonal antibody 62 locoregional 62 adenoma 62 neuroendocrine tumors 62 BRAF mutation 62 HbF 62 antisense inhibition 62 Dasatinib 62 STRIDE PD 62 COX2 61 colorectal liver metastases 61 alvespimycin 61 gefitinib Iressa 61 OXi# 61 glioblastoma multiforme GBM 61 Endometrial cancer 61 malignant neoplasms 61 papillary renal cell carcinoma 61 hematologic disorders 61 Amrubicin 61 plasma kallikrein 61 squamous cell carcinomas 61 metastatic tumors 61 osteoclast activity 61 K ras mutations 61 pulmonary metastasis 61 uPA 61 invasive ductal 61 distant metastases 61 anaplastic 61 invasive aspergillosis 61 relapsed MM 61 secondary hyperparathyroidism 61 Anthracycline 61 leiomyomas 61 tumoral 61 HBeAg negative 61 choroidal neovascularization 61 FLT3 61 MGUS 61 colorectal cancer CRC 61 thromboembolic events 61 SERMs 61 gamma secretase inhibitor 61 precancerous condition 61 pan HDAC inhibitor 61 Neoadjuvant 61 cervical lesions 61 nonsmall cell lung cancer 61 Velcade bortezomib 61 tumor shrinkage 61 neoplasia 61 vandetanib 61 anterior uveitis 61 esophageal carcinoma 61 Tarceva TM 61 grade cervical intraepithelial 61 AQ4N 61 heavily pretreated patients 61 trastuzumab Herceptin ® 61 severe neutropenia 61 JAK inhibitors 61 oral mTOR inhibitor 61 gastroesophageal junction 61 mucinous 61 androgen suppression 61 relapsed ALL 61 leukaemic stem cells 61 bleomycin 61 IL 1ß 61 Neulasta ® 61 oesophageal adenocarcinoma 61 myelofibrosis polycythemia vera 61 epithelial ovarian cancer 61 fibrotic disease 61 mesotheliomas 61 CA4P 61 ankylosing spondylitis AS 61 BRAF gene 61 GIST tumors 61 taxane chemotherapy 61 E#F# 61 B7 H3 61 nonalcoholic steatohepatitis NASH 61 endostatin 61 Tyrima 61 metastatic cancer 61 huN# DM1 61 investigational humanized monoclonal antibody 61 LRP5 61 ADAMTS# 61 ximelagatran 61 pediatric acute lymphoblastic 61 prostate carcinoma 61 squamous 61 prostate cancer mCRPC 61 paclitaxel Taxol ® 61 melanoma tumors 61 sorafenib Nexavar 61 MALT lymphoma 61 BCG refractory 61 Pralatrexate 61 pleomorphic 61 EGFR tyrosine kinase inhibitors 61 metastatic gastric 61 leukemia ALL 61 angiogenesis inhibition 61 demyelination 61 glioblastoma tumors 61 EGF receptor 61 familial ALS 61 Adjuvant chemotherapy 61 fibrotic 61 talabostat 61 pancreatic prostate 61 NKG2D 61 neoplastic 61 Telintra 61 Cholangiocarcinoma 61 invasive bladder 61 SSc 61 docetaxel Taxotere ® 61 seminoma 61 multiple myeloma MM 61 inducible nitric oxide synthase 61 gastrointestinal cancers 61 pancreatic neuroendocrine tumors 61 fallopian tube cancers 61 tumor progression 61 bevacizumab Avastin 61 systemic lupus erythematosus 61 CBLC# 61 PEG SN# 61 anti CD3 61 HNSCC 61 stage IIIB 61 IGF IR 61 HuMax EGFr 61 chronic lymphocytic leukemia CLL 61 EGFR pathway 61 Cloretazine 61 hypoxia inducible factor 61 multi kinase inhibitor 61 nodal metastasis 61 colorectal adenomas 61 TNFa 61 intravenous bisphosphonates 61 Erlotinib 61 radiosensitivity 61 huC# DM4 61 cell acute lymphoblastic 61 Gleevec resistant 61 reperfusion injury 61 T2DM 61 radioiodine therapy 61 adjuvant radiotherapy 61 neovascular 61 metastatic kidney 61 vismodegib 61 Apaziquone 61 elacytarabine 61 androgen receptor AR 61 seliciclib 61 tumors GIST 61 GBM tumors 61 sunitinib malate 61 cediranib 61 metastatic GIST 61 situ CIS 61 cobiprostone 61 systemic lupus erythematosus SLE 61 Akt activation 61 mapatumumab 61 forodesine 61 neoplastic cells 61 Bortezomib 61 remyelination 61 anti EGFR antibody 61 antibody MAb 60 CMV disease 60 luteinizing hormone releasing 60 malignant neoplasm 60 neurotrophic 60 RNAi therapeutic targeting 60 AA amyloidosis 60 hepatic metastases 60 T#I mutant 60 Platinol ® cisplatin 60 NSCLC 60 TRAIL induced apoptosis 60 pancreatic NET 60 demonstrated antitumor activity 60 daunorubicin 60 Myelodysplastic syndromes MDS 60 hypoparathyroidism 60 invasive candidiasis 60 imatinib Gleevec 60 vinca alkaloids 60 idiopathic myelofibrosis 60 medically inoperable 60 oncoprotein 60 Bevacizumab 60 amyloid deposition 60 atypical hyperplasia 60 Lymphocytic 60 osteoclast 60 nucleoside analogues 60 precancerous cervical lesions 60 anti angiogenic drugs 60 IMC A# 60 KRAS oncogene 60 ACZ# 60 JAK2 enzyme 60 cAMP signaling 60 TEMODAL 60 IGF 1R 60 lung cancer NSCLC 60 Carcinoid tumors 60 sulfasalazine 60 TACI Ig 60 Vandetanib 60 chronic GVHD 60 ibandronate 60 zoledronic acid Zometa 60 EGFR mutations 60 zoledronic acid 60 cervical lymph node 60 Zolinza 60 paraganglioma 60 HER2 expression 60 metastatic bone 60 synovial cells 60 lenalidomide dexamethasone 60 lymphocytosis 60 MAGE A3 ASCI 60 Glioblastoma Multiforme 60 Leukemias 60 resectable 60 pro angiogenic 60 lung pancreatic 60 acute myelogenous leukemia AML 60 Mitomycin C 60 tumors 60 CP CPPS 60 Raf MEK ERK 60 vorinostat 60 cytostatic 60 CCX# 60 cystectomy 60 topotecan 60 cutaneous melanoma 60 T#I [002] 60 activin 60 erlotinib Tarceva 60 leukaemias 60 hematologic toxicity 60 EGFR mutant 60 imetelstat 60 Clusterin 60 pelvic lymphadenectomy 60 myeloproliferative disorders 60 eIF 4E 60 antitumor activity 60 EZN 60 kidney urologic 60 basal cell nevus syndrome 60 olaparib 60 Vidofludimus 60 venous thromboembolic events 60 ZD# [001] 60 PCNSL 60 Capecitabine 60 mertansine 60 EGFR HER2 60 deacetylase inhibitors 60 carcinoid tumor 60 CYC# 60 gastric cardia 60 cell carcinomas 60 TACE 60 Factor VIIa 60 neoadjuvant treatment 60 PNP inhibitor 60 Halaven 60 panitumumab Vectibix 60 FASLODEX 60 cyclophosphamide methotrexate 60 Bronchiectasis 60 bone resorption 60 tumor lysis syndrome 60 smoldering myeloma 60 erythropoietic 60 recurrent metastatic 60 IAP inhibitor 60 Gastrointestinal Stromal Tumors 60 pomalidomide 60 presymptomatic 60 T1DM 60 unresectable tumors 60 Basal cell 60 atherosclerotic disease 60 Fas ligand 60 HDACi 60 #ME# 60 osteoporotic 60 WT1 60 tyrosine kinase inhibitor 60 RANK ligand 60 antiandrogen 60 Advanced Renal Cell 60 antitumor effect 60 soft tissue sarcomas 60 TTR gene 60 lung fibrosis 60 Ibritumomab Tiuxetan 60 Anaplastic 60 Aplidin R 60 anti angiogenic therapies 60 keloid scarring 60 proliferative diabetic retinopathy 60 antibody mediated 60 BRAF V#E 60 castrate resistant 60 mTOR mammalian target 60 fibrinolytic 60 cervical lymph nodes 60 upregulating 60 EGFR mutation 60 anti TNF alpha 60 VA# [002] 60 Candida infection 60 renal tumors 60 pleural mesothelioma 60 carboplatin paclitaxel 60 histone deacetylase 60 PsA 60 metastatic hormone refractory 60 prostate tumor 60 Xelox 60 haematological toxicity 60 metastatic 60 activating mutations 60 histone deacetylase inhibitor 60 DMARD 60 severe oral mucositis 60 metastatic renal 60 poly ADP ribose polymerase 60 HCV infection 60 thromboembolic 60 Xanafide 60 chemoradiation 60 urothelial bladder cancer 60 VZV 60 sarcomas 60 renal cell carcinoma 60 adjuvant therapy 60 tumor xenograft models 60 PSN# [002] 60 HPV# 60 neoplasms 60 fibrosis 60 acute promyelocytic leukemia 60 metastatic renal cell 60 Axitinib 60 cytopenia 60 Macrophage 60 Adenomas 60 Acute Myeloid Leukemia AML 60 hormone receptor negative 60 motor neuron degeneration 60 atrophic gastritis 60 liver fibrosis 60 indibulin 60 mitoxantrone 60 cutaneous T 60 CIMZIA ™ 60 radiographic progression 60 Glioma 60 nephrotoxicity 60 neurologic progression 60 c MYC 60 histopathologic examination 60 Vicinium TM 60 sarcoma 60 mutated KRAS gene 60 flutamide 60 gemcitabine Gemzar ® 60 selective modulator 60 H. pylori eradication 60 histone deacetylase inhibitors 60 Epstein Barr virus EBV 60 Ceplene/IL-2 60 benign prostatic hypertrophy BPH 60 hepatic fibrosis 60 proteolytic cleavage 60 elotuzumab 60 radiochemotherapy 60 HSP# inhibitor 60 Zoledronic acid 60 oral prodrug 60 prostate cancer PCa 60 inflammatory lesions 60 biologic therapy 60 phase IIb trial 60 myelodysplastic syndrome MDS 60 neuroendocrine cancers 60 PD LID 60 Chronic Lymphocytic Leukemia CLL 60 nucleotide analog 60 adriamycin 60 transgene expression 60 pancreatic cancers 60 solar keratoses 59 fluoropyrimidine 59 neointimal 59 phosphate S1P 59 LHRH antagonists 59 CEQ# 59 cisplatin 59 tanespimycin 59 recurrent malignant glioma 59 mutated KRAS 59 CaP 59 vasospasm 59 Gliomas 59 pain palliation 59 pro apoptotic 59 KRAS mutations occur 59 bortezomib Velcade 59 situ DCIS 59 histologies 59 IgG1 antibody 59 mutated K ras 59 XELOX 59 bladder ovarian 59 PROCHYMAL 59 Metastases 59 riociguat 59 proteasome inhibitors 59 external genital lesions 59 epithelioid 59 antiangiogenesis 59 contralateral breast 59 cetuximab Erbitux 59 Degarelix 59 Epratuzumab 59 GNAQ 59 HDAC inhibition 59 Panzem 59 gout flares 59 solid tumors 59 atherosclerotic lesions 59 nab paclitaxel 59 Pseudomonas aeruginosa infections 59 clodronate 59 rhIL 7 59 induce apoptosis 59 colorectal neoplasms 59 HGS ETR2 59 HeFH 59 uveal melanoma 59 Temsirolimus 59 carotid plaque 59 antimetabolite 59 mycosis fungoides 59 standard chemotherapy regimen 59 SPINK1 59 corticosteroid dexamethasone 59 glioblastoma 59 EBRT 59 MYCN amplification 59 astrocytomas 59 renal fibrosis 59 chemoresistance 59 radiation sensitizer 59 idarubicin 59 complement inhibitor eculizumab 59 SUTENT 59 delta isoform 59 microtubule inhibitor 59 Barrett esophagus BE 59 axonal damage 59 neoplasias 59 adrenocortical cancer 59 malignant growths 59 mTOR inhibition 59 Dapagliflozin 59 B Cell Lymphoma 59 octreotide LAR 59 herpesviruses 59 cutaneous squamous cell carcinoma 59 mutant p# 59 PIK3CA 59 Medullary thyroid cancer 59 epirubicin 59 GvHD 59 neuroblastoma tumors 59 bronchogenic carcinoma 59 LY# [003] 59 antibody MT# 59 anti mitotic 59 ON #.Na 59 XGEVA 59 PKC inhibitors 59 transplantation HCT 59 PTP 1B 59 idraparinux 59 colorectal tumor 59 ductal cancer 59 aromatase inhibitor therapy 59 LHRH agonist 59 pancreatic colon 59 experimental autoimmune encephalomyelitis 59 hyperplastic 59 IGF1R 59 malignant lesions 59 HER2 receptor 59 HER2 negative 59 Waldenstrom macroglobulinemia 59 malignant lymphoma 59 glucagon receptor 59 PARP inhibition 59 Pleural mesothelioma 59 HDAC Inhibitor 59 TNFalpha 59 Upregulation 59 chemosensitivity 59 APOL1 59 Herceptin trastuzumab 59 TGF beta signaling 59 Folfox 59 F FDG PET 59 lapatinib Tykerb 59 thymic carcinoma 59 diabetic kidney 59 tesmilifene 59 Pathway Inhibitor 59 mutated BRAF gene 59 corticosteroid therapy 59 xenograft tumors 59 IMC #B 59 gadolinium enhanced 59 postoperative atrial fibrillation 59 oral JAK1 59 TORISEL 59 selective inhibition 59 pancreatic islet cell 59 imatinib Gleevec ® 59 HER2 positive tumors 59 ABCB1 59 CsA 59 primary hyperparathyroidism 59 vWF 59 R roscovitine 59 VAPRISOL 59 chemotherapeutic agent 59 BIBW 59 IL# PE#QQR 59 FGFR1 59 adjuvant radiation 59 CIN2 + 59 visilizumab 59 CR# vcMMAE 59 Hurthle cell 59 BRAF V#E mutation 59 hormone deprivation 59 Lymph node 59 immune modulator 59 raloxifene Evista 59 Myelofibrosis 59 Endometrial 59 hedgehog pathway 59 Chronic pancreatitis 59 Exherin TM 59 androgen dependent 59 EndoTAG TM -1 59 Immunohistochemical analysis 59 endometrial 59 hepatoma 59 immunomodulatory 59 antiandrogens 59 fallopian tube carcinoma 59 INGN 59 pathologic fractures 59 nucleoside analog 59 Ozarelix 59 cytotoxic effects 59 ZOLINZA 59 HDAC inhibitors 59 Sentinel node biopsy 59 Amplimexon 59 Bcl xL 59 antiangiogenic agents 59 AP# [003] 59 Cytoxan 59 recurrent VTE 59 imatinib therapy 59 Granulocyte Colony Stimulating Factor 59 molecularly targeted 59 GIST 59 temsirolimus 59 anthracycline taxane 59 Paraplatin ® 59 cerebral vasospasm 59 relapsing remitting MS RRMS 59 cytoreduction 59 prostate cancer HRPC 59 syngeneic 59 glufosfamide 59 APTIVUS r 59 prostatic tissue 59 Adjuvant therapy 59 tyrosine kinase inhibitors TKIs 59 plasma kallikrein inhibitor 59 Prostatitis 59 metastatic prostate 59 apoptotic pathway 59 Azedra 59 radical prostatectomy RP 59 DHFR 59 Metastatic breast cancer 59 cancerous enlargement 59 sorafenib tablets 59 verteporfin 59 ovarian tumors 59 Tumor Necrosis Factor 59 lymphomas 59 Glioblastoma 59 p# mutations 59 Hsp# inhibition 59 thrombotic events 59 protein tyrosine phosphatase 1B 59 lymphatic tissue 59 non squamous NSCLC 59 prostate carcinogenesis 59 CTAP# Capsules 59 BRAF inhibitors 59 obatoclax 59 concurrent chemoradiation 59 immunomodulator 59 5FU 59 Venous thromboembolism 59 Lenocta 59 Introgen ADVEXIN 59 hematopoietic cell 59 tumor subtypes 59 breast endometrial 59 Voreloxin 59 ELACYT 59 synovium 59 Mantle Cell Lymphoma 59 liver resection 59 breast cancer recurrence 59 cardiac dysfunction 59 prostate pancreatic 59 Aflibercept 59 cytotoxic chemotherapy 59 kallikrein 59 bexarotene 59 amenorrhoea 59 prostate cancer AIPC 59 gouty arthritis 59 cyclooxygenase 2 59 demyelinating 59 defibrotide 59 Seliciclib 59 Squalamine 59 kinase inhibitor 59 serine protease 59 organ transplant rejection 59 mTOR kinase 59 FOLFIRI 59 exemestane 59 EGF receptors 59 Prolongs Survival 59 clinically localized prostate 59 ATTR CM 59 grade dysplasia 59 anticancer therapy 59 bortezomib 59 Torisel 59 membranous nephropathy 59 mouse xenograft models 59 surgical debulking 59 interferon alfa 59 Tanespimycin 59 FOLFIRI alone 59 endocrine therapies 59 antiestrogen 59 radionuclide therapy 59 prostate carcinomas 59 Camptosar ® irinotecan 59 XmAb# 59 taxane therapy 59 Androgen deprivation therapy 59 KRAS mutations 59 bevacizumab Avastin ® 59 cholangiocarcinoma 59 polypoid 59 immune dysregulation 59 epithelial cancers 59 malignant phenotype 59 Hormone Refractory Prostate Cancer 59 E cadherin expression 59 indolent lymphomas 59 grade serous ovarian 59 Orally administered 59 lung adenocarcinomas 59 retinoic acid receptor 59 Tyrosine Kinase Inhibitors 59 thymidylate synthase TS 59 cartilage degeneration 59 MYLOTARG 59 malignant transformation 59 heterotopic ossification 59 sustained virologic response 59 VEGF inhibition 59 arterial thrombosis 59 geographic atrophy 59 serum phosphate 59 potent antiproliferative 59 herpes zoster shingles 59 carcinomas 59 Factor Receptor 59 Radical prostatectomy 59 Basal cell carcinoma 59 angiogenesis inhibitors 59 ALN TTR 59 trastuzumab 59 Cardiotoxicity 59 FDG-PET/CT 59 antitumour activity 59 metaplasia 59 irinotecan chemotherapy 59 pancreatic lung 59 cinacalcet 59 leiomyoma 59 histone deacetylase HDAC inhibitor 59 malignant pancreatic